This article is more than 5 years old. Information may no longer be current.

Oramed received allowance for key patent on oral exenatide

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Oramed Pharmaceuticals received allowance for a patent entitled, “Methods and Compositions for Oral Administration of Exenatide” from the Israeli Patent Office, according to a press release.

The patent covers oral exenatide compositions made using the company’s proprietary technology.

Exenatide (Byetta, Bydureon; Amylin) is a GLP-1 analog currently marketed in injectable form and indicated for the treatment of type 2 diabetes.

Oramed is seeking to develop an oral insulin capsule (ORMD-0801), which is currently in phase 2 clinical trials in patients with type 2 diabetes under an investigational new drug application with the FDA, and an oral exenatide capsule (ORMD-0901), with trials on healthy volunteers (phase 1b) and patients with type 2 diabetes (phase 2a) underway, according to the press release.